However, there are few reports to guide the treatment of HER2‐positive breast cancer patients with brain metastasis, and the treatment resistance to anti‐HER2 therapy as well as its occasional intolerable adverse reactions remains to be a challenge, highlighting a clear urgent demand for more novel therapies.13 Here, ERBB2 is linked to breast carcinoma.